We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
CStone Pharmaceuticals (Suzhou) Co., Ltd. announced the updated results from two studies of its anti-PD-L1 monoclonal antibody sugemalimab (CS1001) at the 2020 Chinese Society of Clinical Oncology (CSCO) Annual Meeting.
The CS1001-201 trial reported in the abstract is a single-arm, multi-centre Phase II clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of CS1001 monotherapy in relapsed or refractory extranodal natural killer (